{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:07:44Z","timestamp":1768291664476,"version":"3.49.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.cld.2011.12.007","type":"journal-article","created":{"date-parts":[[2012,2,6]],"date-time":"2012-02-06T20:26:09Z","timestamp":1328559969000},"page":"73-89","source":"Crossref","is-referenced-by-count":11,"title":["Management of Overt Hepatic Encephalopathy"],"prefix":"10.1016","volume":"16","author":[{"given":"Vandana","family":"Khungar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Poordad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2011.12.007_bib1","series-title":"Diagnosis and management of liver disease","first-page":"140","article-title":"Hepatic encephalopathy","author":"Voight","year":"1995"},{"issue":"4","key":"10.1016\/j.cld.2011.12.007_bib2","first-page":"222","article-title":"Current concepts in the pathophysiology and management of hepatic encephalopathy","volume":"7","author":"Frederick","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2011.12.007_bib3","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/jhep.2002.31250","article-title":"Hepatic encephalopathy\u2014definition, nomenclature, diagnosis and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna 1998","volume":"35","author":"Ferenci","year":"2002","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2011.12.007_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1746-6342.2006.03215.x","article-title":"Review article: the burden of hepatic encephalopathy","volume":"25","author":"Poordad","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2011.12.007_bib5","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1111\/j.1572-0241.2001.04130.x","article-title":"Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy","volume":"96","author":"Romero-Gomez","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2011.12.007_bib6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/hep.20559","article-title":"American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension","volume":"41","author":"Boyer","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2011.12.007_bib7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10620-006-9442-4","article-title":"Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy","volume":"52","author":"Leevy","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2011.12.007_bib8","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/ajg.2011.157","article-title":"The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers","volume":"106","author":"Bajaj","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2011.12.007_bib9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jclinepi.2009.06.014","article-title":"Short-form Zarit caregiver burden interviews were valid in advanced conditions","volume":"63","author":"Higginson","year":"2010","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cld.2011.12.007_bib10","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0168-8278(99)80144-5","article-title":"Prognostic significance of hepatic encephalopathy in patients with cirrhosis","volume":"30","author":"Bustamante","year":"1999","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2011.12.007_bib11","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/lt.21129","article-title":"Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease","volume":"13","author":"Stewart","year":"2007","journal-title":"Liver Transpl"},{"issue":"7","key":"10.1016\/j.cld.2011.12.007_bib12","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1053\/j.gastro.2010.02.015","article-title":"Persistence of cognitive impairment after resolution of overt hepatic encephalopathy","volume":"138","author":"Bajaj","year":"2010","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2011.12.007_bib13","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S0168-8278(10)60152-3","article-title":"Severity of chronic cognitive impairment in cirrhosis increases with number of episodes of overt hepatic encephalopathy","volume":"52","author":"Bajaj","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2011.12.007_bib14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jcrc.2009.01.008","article-title":"Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy","volume":"24","author":"Fichet","year":"2009","journal-title":"J\u00a0Crit Care"},{"key":"10.1016\/j.cld.2011.12.007_bib15","series-title":"The hepatic coma syndromes and lactulose","author":"Conn","year":"1979"},{"key":"10.1016\/j.cld.2011.12.007_bib16","first-page":"569","article-title":"Hepatic encephalopathy","volume":"vol. 1","author":"Cordoba","year":"2007"},{"key":"10.1016\/j.cld.2011.12.007_bib17","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/ajg.2009.160","article-title":"Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy","volume":"104","author":"Hassanein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2011.12.007_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00042737-200012020-00012","article-title":"Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study","volume":"12","author":"Williams","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2011.12.007_bib19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0016-5085(77)80135-2","article-title":"Comparison of lactulose and neomycin in the treatment of chronic portal-systemic-encephalopathy: a double blind controlled trial","volume":"72","author":"Conn","year":"1977","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2011.12.007_bib20","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1111\/j.1572-0241.2001.03964.x","article-title":"Hepatic encephalopathy","volume":"96","author":"Blei","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.cld.2011.12.007_bib21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJM199708143370707","article-title":"Treatment of hepatic encephalopathy","volume":"337","author":"Riordan","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2011.12.007_bib22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.mcna.2008.03.009","article-title":"Hepatic encephalopathy","volume":"92","author":"Munoz","year":"2008","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.cld.2011.12.007_bib23","first-page":"6","article-title":"Hepatic encephalopathy: are NH4 levels and protein restriction obsolete?","volume":"95","author":"Caruana","year":"2011","journal-title":"Pract Gastroenterol"},{"key":"10.1016\/j.cld.2011.12.007_bib24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11011-007-9060-7","article-title":"The treatment of hepatic encephalopathy","volume":"22","author":"Morgan","year":"2007","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.cld.2011.12.007_bib25","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/bmj.38048.506134.EE","article-title":"Non-absorbable disaccharides for hepatic encephalopathy:systematic review of randomized trials","volume":"328","author":"Als-Nielsen","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.cld.2011.12.007_bib26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2011.12.007_bib27","first-page":"482","article-title":"Lack of preventive effect of branched-chain amino acid solution on postoperative hepatic encephalopathy in patients with cirrhosis: a randomized, prospective trial","volume":"104","author":"Kanematsu","year":"1988","journal-title":"Surgery"},{"key":"10.1016\/j.cld.2011.12.007_bib28","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/hep.21930","article-title":"Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis","volume":"46","author":"Hassanein","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2011.12.007_bib29","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1053\/j.gastro.2009.05.056","article-title":"Secondary prophylaxis of hepatic encephalopathy: an open label randomized controlled trial of lactulose versus placebo","volume":"137","author":"Sharma","year":"2009","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.cld.2011.12.007_bib30","first-page":"1057","article-title":"Is the intestinal lavage with a solution of mannitol effective in the prevention of post-hemorrhagic hepatic encephalopathy in patients with liver cirrhosis? results of a randomized prospective study","volume":"18","author":"Rolachon","year":"1994","journal-title":"Gastroenterol Clin Biol"},{"issue":"4","key":"10.1016\/j.cld.2011.12.007_bib31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/hep.1840070404","article-title":"Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial","volume":"7","author":"Uribe","year":"1987","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2011.12.007_bib32","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/hep.510250609","article-title":"Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study","volume":"25","author":"Kircheis","year":"1997","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2011.12.007_bib33","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0168-8278(98)80237-7","article-title":"Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study","volume":"28","author":"Stauch","year":"1998","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2011.12.007_bib34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.1840160123","article-title":"Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial","volume":"16","author":"Sushma","year":"1992","journal-title":"Hepatology"},{"issue":"8401","key":"10.1016\/j.cld.2011.12.007_bib35","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(84)92567-4","article-title":"Oral zinc supplementation improves hepatic encephalopathy. Results of a randomized controlled trial","volume":"2","author":"Reding","year":"1984","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.cld.2011.12.007_bib36","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1007\/BF01307509","article-title":"Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial","volume":"36","author":"Riggio","year":"1991","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2011.12.007_bib37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/lt.21593","article-title":"Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation","volume":"15","author":"Sotil","year":"2009","journal-title":"Liver Transpl"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2011.12.007_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1746-6342.2006.03218.x","article-title":"Review article the current pharmacological therapies for hepatic encephalopathy","volume":"25","author":"Bass","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2011.12.007_bib39","first-page":"683","article-title":"Precipitating factors of hepatic encephalopathy at a tertiary care hospital Jamshoro, Hyderabad","volume":"59","author":"Devrajani","year":"2009","journal-title":"J\u00a0Pak Med Assoc"},{"key":"10.1016\/j.cld.2011.12.007_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1665-2681(19)32157-X","article-title":"Bacterial infections associated with hepatic encephalopathy: prevalence and outcome","volume":"2","author":"Strauss","year":"2003","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.cld.2011.12.007_bib41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1443-1661.2005.00426.x","article-title":"Endoscopic coagulation therapy is successful for improving encephalopathy in cirrhotic patients with gastric antral vascular ectasia","volume":"17","author":"Zushi","year":"2005","journal-title":"Dig Endosc"},{"key":"10.1016\/j.cld.2011.12.007_bib42","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/gut.52.7.1041","article-title":"Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver","volume":"52","author":"Jalan","year":"2003","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2011.12.007_bib43","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0168-8278(09)60107-0","article-title":"Phase 2, multicenter, randomized study of AST-120 (spherical carbon adsorbent) vs. lactulose in the treatment of low-grade hepatic encephalopathy","volume":"50","author":"Pockros","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2011.12.007_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/hep.510310107","article-title":"Partial pressure of ammonia versus ammonia in hepatic encephalopathy","volume":"31","author":"Kramer","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2011.12.007_bib45","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0002-9343(02)01477-8","article-title":"Correlation between ammonia levels and the severity of hepatic encephalopathy","volume":"114","author":"Ong","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.cld.2011.12.007_bib46","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/gut.46.6.849","article-title":"Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration","volume":"46","author":"Plauth","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.cld.2011.12.007_bib47","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1053\/gast.2003.50062","article-title":"Liver transplantation improves hepatic myelopathy: evidence by three cases","volume":"124","author":"Weissenborn","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2011.12.007_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003044.pub2","article-title":"Nonabsorbable disaccharides for hepatic encephalopathy","volume":"2","author":"Als-Nielsen","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.cld.2011.12.007_bib49","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/ajg.2011.182","article-title":"Lactulose: how many ways can one drug be prescribed?","volume":"106","author":"Lukers","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 9","key":"10.1016\/j.cld.2011.12.007_bib50","first-page":"1","article-title":"Treatment of patients with hepatic encephalopathy: review of the latest data from EASL 2011","volume":"7","author":"Bass","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2011.12.007_bib51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MEG.0b013e328330a8d3","article-title":"Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy","volume":"22","author":"Malaguarnera","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2011.12.007_bib52","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hep.20481","article-title":"Dietary fiber decreases ammonia levels in patients with cirrhosis","volume":"41","author":"Iwasa","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2011.12.007_bib53","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/hep.20194","article-title":"Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis","volume":"39","author":"Liu","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2011.12.007_bib54","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.3748\/wjg.v16.i27.3347","article-title":"Changing face of hepatic encephalopathy: role of inflammation and oxidative stress","volume":"16","author":"Seyan","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2011.12.007_bib55","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1542-3565(04)00667-6","article-title":"A\u00a0randomized controlled trial of acarbose in hepatic encephalopathy","volume":"3","author":"Gentile","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2011.12.007_bib56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1586\/14787210.3.2.201","article-title":"Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections","volume":"3","author":"Gerard","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2011.12.007_bib57","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000081991","article-title":"Rifaximin: in\u00a0vitro and in\u00a0vivo antibacterial activity\u2014a review","volume":"51","author":"Jiang","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cld.2011.12.007_bib58","first-page":"186","article-title":"Effects of rifaximin on bacterial virulence mechanisms at supra-and sub-inhibitory concentrations","volume":"20","author":"Debbia","year":"2008","journal-title":"J\u00a0Chemother"},{"issue":"8","key":"10.1016\/j.cld.2011.12.007_bib59","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2036.2011.04808.x","article-title":"Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy\u2014a double-blind placebo-controlled study","volume":"34","author":"Sanyal","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2011.12.007_bib60","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(10)60017-7","article-title":"Rifaximin treatment improved quality of life in patients with hepatic encephalopathy: results of a large, randomized, placebo-controlled trial","volume":"52","author":"Sanyal","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"6 Suppl 9","key":"10.1016\/j.cld.2011.12.007_bib61","first-page":"1","article-title":"Long term efficacy and survival in patients treated with the gut-selective antibiotic rifaximin (550 mg BID) for the maintenance of remission from overt hepatic encephalopathy","volume":"7","author":"Mullen","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2011.12.007_bib62","series-title":"Long-term administration of rifaximin improves the prognosis of patients with alcohol-related decompensated cirrhosis: a case-control study","author":"Vlachogiannakos","year":"2011"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2011.12.007_bib63","first-page":"331A","article-title":"Impact of rifaximin treatment on survival in patients with end-stage liver disease","volume":"52","author":"Leise","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2011.12.007_bib64","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2710.2009.01120.x","article-title":"Naloxone in the management of hepatic encephalopathy","volume":"35","author":"Jiang","year":"2010","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.cld.2011.12.007_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002798.pub2","article-title":"Benzodiazepine receptor antagonists for hepatic encephalopathy","volume":"2","author":"Als-Nielsen","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2011.12.007_bib66","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0168-8278(10)60154-7","article-title":"Transdermal rivastigmine for treatment of encephalopathy in liver cirrhosis\u2014a randomized placebo controlled trial (TREC TRIAL)","volume":"52","author":"Basu","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2011.12.007_bib67","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jhep.2004.03.023","article-title":"Normal protein diet for episodic hepatic encephalopathy: results of a randomized study","volume":"41","author":"Cordoba","year":"2004","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2011.12.007_bib68","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2036.2009.04211.x","article-title":"Review article: the modern management of hepatic encephalopathy","volume":"31","author":"Bajaj","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"6 Suppl 9","key":"10.1016\/j.cld.2011.12.007_bib69","first-page":"1","article-title":"Chronic hepatic encephalopathy (HE) in patients with severe liver cirrhosis: efficacy of the wheat and milk protein free diet in the reduction of clinical episodes","volume":"7","author":"Balzola","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2011.12.007_bib70","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1365-2036.2010.04448.x","article-title":"Clinical trial: oral zinc in hepatic encephalopathy","volume":"32","author":"Takuma","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2011.12.007_bib71","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1440-1746.2008.05582.x","article-title":"L-ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis","volume":"24","author":"Jiang","year":"2009","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2011.12.007_bib72","series-title":"Ocera therapeutics completes first in human studies with OCR-002 for the treatment of hyperammonemia and hepatic encephalopathy","year":"2010"},{"key":"10.1016\/j.cld.2011.12.007_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001939","article-title":"Branched-chain amino acids for hepatic encephalopathy","volume":"2","author":"Als-Nielsen","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.cld.2011.12.007_bib74","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11011-011-9260-z","article-title":"Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial","volume":"26","author":"Malaguarnera","year":"2011","journal-title":"Metab Brain Dis"},{"issue":"5","key":"10.1016\/j.cld.2011.12.007_bib75","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2004.12.028","article-title":"Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study","volume":"42","author":"Riggio","year":"2005","journal-title":"J\u00a0Hepatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326111001334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326111001334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T19:47:37Z","timestamp":1593632857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326111001334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1089326111001334"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2011.12.007","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}